Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Potential Role of Apo B in the Risk Stratification of Type 2 Diabetic Patients with Dyslipidemia


Affiliations
1 Department of Clinical Pathology, Sree Siddhartha Medical College and Research Centre Sree Siddhartha University, Tumkur, Karnataka, India
2 Department of Medicine, Sree Siddhartha Medical College and Research Centre Sree Siddhartha University, Tumkur, Karnataka, India
     

   Subscribe/Renew Journal


Background: Dyslipidemia matters in type 2 diabetes and appreciation of the lipid abnormalities in diabetes has changed with time. There are few data on Apo B levels in these patients and consequently there is little information on the frequencies of the various dyslipidemic phenotypes.

Methods: Plasma lipids and Apo B were measured by standardized methods. The patients were categorized by two different methods. The first was based on triglyceride (<150mg/dl) and LDL cholesterol (<100mg/dl), and the second was based on triglyceride (<150mg/dl) and Apo B (<137mg/dl).

Results: As overall, plasma triglycerides were elevated, total and LDL cholesterol were normal and HDL was decreased. Results of the phenotyping analysis were, using the conventional approach; only 20% has elevated LDL cholesterol. Using the new approach, 63% has an elevated Apo B and therefore an elevated LDL particle number. The mean LDLc for hypertriglceridemic-hyperapo B group was 120.4mg/dl, whereas the mean Apo B for the same was 239mg/dl, indicating its significance over LDL cholesterol.

Conclusion: Diagnosis based on triglycerides and Apo B revealed more number of patients with atherogenic, dyslipidemic status rather than by diagnosing on triglycerides and LDL cholesterol levels. Apo B is a better cardiovascular risk marker and can replace LDL cholesterol in maintaining statin therapy in type 2 diabetic patients.


Keywords

Apo B, Dyslipidemia, Cardiovascular Risk, Type 2 Diabetes
Subscription Login to verify subscription
User
Notifications
Font Size



  • A Potential Role of Apo B in the Risk Stratification of Type 2 Diabetic Patients with Dyslipidemia

Abstract Views: 413  |  PDF Views: 0

Authors

C. A. Arathi
Department of Clinical Pathology, Sree Siddhartha Medical College and Research Centre Sree Siddhartha University, Tumkur, Karnataka, India
N. Prabhudeva
Department of Medicine, Sree Siddhartha Medical College and Research Centre Sree Siddhartha University, Tumkur, Karnataka, India
J. P. Geetha
Department of Clinical Pathology, Sree Siddhartha Medical College and Research Centre Sree Siddhartha University, Tumkur, Karnataka, India

Abstract


Background: Dyslipidemia matters in type 2 diabetes and appreciation of the lipid abnormalities in diabetes has changed with time. There are few data on Apo B levels in these patients and consequently there is little information on the frequencies of the various dyslipidemic phenotypes.

Methods: Plasma lipids and Apo B were measured by standardized methods. The patients were categorized by two different methods. The first was based on triglyceride (<150mg/dl) and LDL cholesterol (<100mg/dl), and the second was based on triglyceride (<150mg/dl) and Apo B (<137mg/dl).

Results: As overall, plasma triglycerides were elevated, total and LDL cholesterol were normal and HDL was decreased. Results of the phenotyping analysis were, using the conventional approach; only 20% has elevated LDL cholesterol. Using the new approach, 63% has an elevated Apo B and therefore an elevated LDL particle number. The mean LDLc for hypertriglceridemic-hyperapo B group was 120.4mg/dl, whereas the mean Apo B for the same was 239mg/dl, indicating its significance over LDL cholesterol.

Conclusion: Diagnosis based on triglycerides and Apo B revealed more number of patients with atherogenic, dyslipidemic status rather than by diagnosing on triglycerides and LDL cholesterol levels. Apo B is a better cardiovascular risk marker and can replace LDL cholesterol in maintaining statin therapy in type 2 diabetic patients.


Keywords


Apo B, Dyslipidemia, Cardiovascular Risk, Type 2 Diabetes

References